baito logo
    navigation?.buttons?.createJob?.text
    Fire
    new
    CatalYm GmbH header
    CatalYm GmbH logo
    #immuntherapie #krebsforschung #biotech

    CatalYm GmbH

    from Planegg

    Option 1 (Focus on Innovation):

    CatalYm GmbH develops innovative immunotherapies against cancer. Focus: GDF-15 neutralization to overcome therapy resistance. Location: Martinsried near Munich.

    Option 2 (Focus on Mission):

    CatalYm GmbH improves cancer treatment through innovative immunotherapies. Goal: Overcome therapy resistance & give patients hope. Seat: Martinsried.

    Option 3 (Combination of both):

    CatalYm GmbH: Pioneer in immunotherapy against cancer. Development of innovative solutions to overcome therapy resistance. Location: Martinsried.

    Visit websiteArrowRight

    CatalYm GmbH is an innovative biotechnology company based in Martinsried near Munich, specializing in the development of novel immunotherapies for the treatment of cancer. Since its founding in 2016 as a spin-off from the University of Würzburg, CatalYm GmbH has been pursuing the goal of decisively improving immunotherapy in solid tumors through targeted neutralization of a key resistance mechanism[1][3][4].

    At the center of CatalYm GmbH's research is the discovery and therapeutic blockade of GDF-15, an immunosuppressive protein used by tumors to escape the body's own immune defenses. The leading drug candidate program visugromab (CTL-002) is a GDF-15-neutralizing monoclonal antibody that has already shown convincing data regarding efficacy and tolerability in clinical Phase 1/2 studies. In particular, in combination with established checkpoint inhibitors, visugromab was able to significantly improve the response even in patients with resistant tumors and inhibit tumor growth[1][4]. In addition, visugromab shows positive effects against cachexia caused by cancer and therapies, a serious muscle wasting syndrome, which further underscores the therapeutic benefit[1].

    CatalYm GmbH pursues a clear mission: to push the boundaries of cancer treatment by overcoming the therapeutic obstacles that leave many patients with a poor prognosis through innovative scientific approaches. The patient is at the center of attention - the company particularly addresses the challenge of therapy resistance, which is one of the most important causes of therapy failure and reduced quality of life in cancer patients. With a highly qualified team and the support of renowned investors, CatalYm GmbH relies on excellent research, clinical development and collaboration with international partners to make visugromab widely available as a new, effective immunotherapy[1][3][5].

    Sustainability at CatalYm GmbH is primarily reflected in the consistent focus on medical progress and improved patient outcomes. The development of innovative therapies that not only increase efficacy but also mitigate side effects and comorbidities such as cachexia contributes to a sustainable improvement in cancer care. In addition, the company is actively involved in exchanging ideas with the professional community through its participation in leading scientific congresses, such as the Else Kröner-Symposium 2025 or the AACR conference, in order to advance progress in immuno-oncology[1].

    CatalYm GmbH is expanding its international presence, with plans to open an office in Boston and conduct clinical trials in the USA. With around 40 employees, the company combines multidisciplinary expertise in research and development to advance the next generation of immunotherapy and achieve sustainable success for patients with difficult-to-treat cancers[5].

    Summary:

    • Development of novel immunotherapies against GDF-15-mediated tumor resistance
    • Leading product visugromab: GDF-15-neutralizing antibody with promising clinical results
    • Focus on overcoming therapy resistance and treating cachexia
    • Mission: Improving the life expectancy and quality of life of cancer patients through innovative science
    • Sustainable commitment to medical progress and international collaboration
    • Based in Martinsried; expanding its presence in the USA with clinical development in Boston

    CatalYm GmbH stands for groundbreaking research in immuno-oncology and is dedicated with passion and expertise to the development of new therapeutic solutions that give hope to patients with difficult-to-treat cancers.

    Sources:

    Edit
    Edit